Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Tumor, Pediatric
- Brain Tumors
- Quality of Life
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study is a two-arm, parallel group, randomised controlled trial comparing ACT with waitlist controls who will then receive ACT after the 3-month waiting period. Participants will be randomised on a 1:1 ratio to receive 12-weeks of treatment either immediately or following a 12-week wait. The treatment will be DNA-v which is a model of ACT adapted to those aged 11-24 years. The model will be further adapted for those who have undergone brain tumour treatment. As trial therapists will perform assessments, blinding is not possible. Follow-up assessments will be conducted at 12-, 24-, 36-, and 48-weeks post-randomisation with primary end point at 12-weeks.Masking: None (Open Label)Masking Description: As trial therapists will perform assessments, blinding is not possible.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 11 years and 24 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04722237
- Collaborators
- University of Nottingham
- University Hospitals Bristol and Weston NHS Foundation Trust
- Newcastle-upon-Tyne Hospitals NHS Trust
- University of Exeter
- Great Ormond Street Hospital for Children NHS Foundation Trust
- University of Surrey
- Newcastle University
- University of Bristol
- DNA-v International
- Investigators
- Principal Investigator: Sophie Thomas, DClinPsy Nottingham University Hospitals NHS Trust
Get Well Soon